NRD135S E1

Drug Profile

NRD135S E1

Alternative Names: NRD135S-E1

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novaremed
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Protein tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain

Most Recent Events

  • 05 Sep 2017 NRD135S E1 is still in phase II development for Neuropathic pain in Israel (PO) (Novaremed pipeline, September 2017)
  • 25 Jul 2016 Novaremed completes a phase II trial in Neuropathic pain in Israel (PO) (NCT02345291)
  • 01 Apr 2015 Phase-II clinical trials in Neuropathic pain in Israel (PO) (NCT02345291)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top